WO1997008205B1 - Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo - Google Patents
Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivoInfo
- Publication number
- WO1997008205B1 WO1997008205B1 PCT/EP1996/003734 EP9603734W WO9708205B1 WO 1997008205 B1 WO1997008205 B1 WO 1997008205B1 EP 9603734 W EP9603734 W EP 9603734W WO 9708205 B1 WO9708205 B1 WO 9708205B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antigen
- tumor
- antigens
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
L'invention concerne des anticorps présentant deux spécificités ou plus, identifiant deux différents antigènes situés sur une cellule tumorale, ainsi que des médicaments et des compositions diagnostiques contenant lesdits anticorps. Les anticorps et les médicaments décrits s'utilisent notamment pour l'identification et l'élimination spécifiques de cellules tumorales in vivo ou in vitro.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1995131348 DE19531348A1 (de) | 1995-08-25 | 1995-08-25 | Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo |
| DE19531348.8 | 1995-08-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997008205A1 WO1997008205A1 (fr) | 1997-03-06 |
| WO1997008205B1 true WO1997008205B1 (fr) | 1997-05-15 |
Family
ID=7770410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1996/003734 Ceased WO1997008205A1 (fr) | 1995-08-25 | 1996-08-23 | Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE19531348A1 (fr) |
| WO (1) | WO1997008205A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2753368B1 (fr) | 1996-09-13 | 1999-01-08 | Chauvin Jean Luc | Cage d'osteosynthese expansive |
| PL199747B1 (pl) * | 1998-04-21 | 2008-10-31 | Micromet Ag | Jednołańcuchowy wielofunkcyjny polipeptyd, polinukleotyd, wektor, komórka, sposób wytwarzania polipeptydu, kompozycja, zastosowanie polipeptydu lub wektora lub polinukleotydu i zastosowanie polinukleotydu lub wektora oraz sposób identyfikacji aktywatorów lub inhibitorów aktywacji lub stymulacji komórek T |
| DE10034607A1 (de) | 2000-07-20 | 2002-02-07 | Gundram Jung | Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| AT413486B (de) * | 2002-07-03 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung eines antikörpers gerichtet gegen lewis-antigene |
| AT500648B1 (de) | 2002-08-12 | 2010-03-15 | Igeneon Krebs Immuntherapie | Set zur behandlung von krebspatienten |
| WO2004106381A1 (fr) | 2003-05-31 | 2004-12-09 | Micromet Ag | Compositions pharmaceutiques comprenant des constructions d'anticorps anti-cd3, anti-cd19 bispecifiques pour le traitement de troubles associes aux lymphocytes b |
| EP1629013B1 (fr) | 2003-05-31 | 2018-01-24 | Amgen Research (Munich) GmbH | Composition pharmaceutique comprenant un anticorps bispecifique destinee a epcam |
| WO2015187937A1 (fr) | 2014-06-04 | 2015-12-10 | Wenzel Spine, Inc. | Dispositif de fusion de corps intervertébral à extension bilatérale |
| MX392900B (es) | 2017-02-07 | 2025-03-24 | Oblique Therapeutics Ab | Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer |
| US11219531B2 (en) | 2019-04-10 | 2022-01-11 | Wenzel Spine, Inc. | Rotatable intervertebral spacing implant |
| EP3972998A1 (fr) | 2019-05-21 | 2022-03-30 | Novartis AG | Molécules de liaison à cd19 et utilisations de celles-ci |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4978745A (en) * | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| WO1991003493A1 (fr) * | 1989-08-29 | 1991-03-21 | The University Of Southampton | CONJUGUES F(ab)3 ou F(ab)4 bi ou trispécifiques |
| ZA914625B (en) * | 1990-06-22 | 1993-02-24 | Lilly Co Eli | In vivo targeting with bifunctional antibodies |
| DE4028955A1 (de) * | 1990-09-12 | 1992-03-19 | Boehringer Mannheim Gmbh | Monoklonale antikoerper gegen den interleukin 2-rezeptor |
| FR2672291A1 (fr) * | 1991-01-31 | 1992-08-07 | Inst Nat Sante Rech Med | Composition d'anticorps diriges contre le recepteur de l'interleukine-2 humaine ou animale. |
| CA2113578A1 (fr) * | 1991-07-19 | 1993-02-04 | Ann E. Huang | Composes trifonctionnels specifiques de cellules multiresistantes |
| JPH08510116A (ja) * | 1993-04-09 | 1996-10-29 | カイロン コーポレイション | 二重特異性抗原結合分子 |
-
1995
- 1995-08-25 DE DE1995131348 patent/DE19531348A1/de not_active Withdrawn
-
1996
- 1996-08-23 WO PCT/EP1996/003734 patent/WO1997008205A1/fr not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997008205B1 (fr) | Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo | |
| Mezzanzanica et al. | Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components | |
| US4978745A (en) | Immunoreactive heterochain antibodies | |
| Weiner et al. | Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII | |
| AU761387B2 (en) | Bispecific antibodies for retargeting anticancer cytotoxic lymphocytes and hybriomas and monoclonal antibodies therefore | |
| Hombach et al. | A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA | |
| Heuser et al. | T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells | |
| MY108519A (en) | Novel antibodies reactive with human carcinomas. | |
| US6294167B1 (en) | Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated | |
| EP0256654A3 (fr) | Immunoglobuline chimère murine-humaine, spécifique pour l' antigène 17-1A associés aux tumeurs | |
| WO1997007819B1 (fr) | Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter | |
| EP0369566A2 (fr) | Anticorps chimériques bifonctionnels | |
| DE69033181T2 (de) | Iga-rezeptorspezifische monoklonale antikörper | |
| Lloyd | Human tumor antigens: detection and characterization with monoclonal antibodies | |
| Dorvillius et al. | Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen | |
| Thompson et al. | Monoclonal antibodies to human colon and colorectal carcinoma | |
| Carroll et al. | Idiotype variant cell populations in patients with B cell lymphoma. | |
| Michon et al. | In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody | |
| HUP9901597A2 (hu) | Eljárás nemkívánt célsejtek elpusztítására | |
| DE19531348A1 (de) | Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo | |
| de Gast et al. | Clinical perspectives of bispecific antibodies in cancer | |
| Liao et al. | Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies | |
| Holzer et al. | Superantigen-staphylococal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells | |
| Bosslet et al. | Immunological tailoring of monoclonal antibodies for immunotherapy of pancreatic carcinoma | |
| Palumbo et al. | Multiple independent immunoglobulin class‐switch recombinations occurring within the same clone in myeloma |